Matthew Kaplan - May 12, 2022 Form 4 Insider Report for Nuvectis Pharma, Inc. (NVCT)

Role
Director
Signature
/s/ Matthew Kaplan
Stock symbol
NVCT
Transactions as of
May 12, 2022
Transactions value $
$50,633
Form type
4
Date filed
5/16/2022, 08:32 AM
Previous filing
Apr 5, 2022
Next filing
Jun 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVCT Common Stock Purchase $18.8K +1.18K +3.59% $15.96 33.9K May 12, 2022 Direct F1
transaction NVCT Common Stock Purchase $31.8K +1.82K +5.37% $17.47 35.8K May 12, 2022 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the weighted average purchase price. The range of prices for the shares purchased was $15.75 to $16.00. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.
F2 Reflects the weighted average purchase price. The range of prices for the shares purchased was $17.33 to $17.50. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.